

8 September 2015

Suite 1, 1233 High Street  
Armadale VIC 3142

## **Imugene Announces Successful Capital Raising**

- \$3m in placement commitments to sophisticated investors at a price of \$0.0075 (0.75 cents) per share, subject to shareholder approval at the company's upcoming annual general meeting;
- Attaching options on a 1:2 basis to be issued with placement shares at 1.5 cents exercise price, expiring on 31 March 2017; and
- Bonus loyalty options on a 2:15 basis, on the same terms as the placement options, intended to be issued to all eligible shareholders, except newly issued shares, in Australia and New Zealand.

---

The Board of Imugene Limited (ASX: IMU) (**Imugene**) announces today that it has received firm commitments for a placement of \$3m at an issue price of \$0.0075 (0.75 cents) per share from sophisticated investor clients of Forrest Capital.

The placement comprises the issue of fully-paid ordinary shares and is subject to approval by shareholders at the company's AGM currently scheduled for on or around 15 October, 2015.

New investors will also receive a one for two (1:2) options for each placement share issued with an exercise price of 1.5 cents per share and expiring on 31 March 2017. The issue of the options is also subject to approval by shareholders at the company's AGM.

It is currently intended that all eligible shareholders in Australia and New Zealand, including those not able to participate in the placement will be granted, for nil consideration, 2 options for every 15 shares held in the company. The options will be to subscribe for an ordinary share in the company at 1.5 cents per share, on the same terms as the participants in the placement options. The company expects to issue a prospectus for these options and will advise the market of the specific timings for this transaction, by means of a separate release.

All options are intended to be listed on the Australian Securities Exchange.

The Company's Executive Chairman, Paul Hopper said "We are delighted to welcome new and existing shareholders to Imugene in this placement. The funds raised from this placement, subject to shareholder approval, in addition to our existing cash position, places us in a strong position to move ahead with our programme. With our newly appointed COO, Ms. Leslie Chong, commencing her role shortly and the start of clinical trials, we look forward to an exciting time ahead for Imugene."

Having significantly addressed establishing GMP quality manufacturing for HER-Vaxx, the next step is to begin clinical trials for HER-Vaxx. The company has already appointed a CRO with significant oncology expertise and is targeting late this year or early 2016 to commence the Phase 1b trial. Funds raised are intended to be applied primarily to initiation of the company's Phase 1b/2 clinical trial in patients with metastatic gastric cancer and additional preclinical work on HER-Vaxx drug combinations.

The capital raising includes a subscription by Otto Buttula, a Non-Executive Director of the company, for shares amounting to \$225,000 and Charles Walker, a Non-Executive Director of the company, for shares amounting to \$11,250. Messrs Buttula and Walker's subscription will also be subject to shareholder approval at the company's annual general meeting.

Investors looking for further information should refer to the company's website ([www.imugene.com](http://www.imugene.com)), which includes corporate videos and other information.

Contact:

**Paul Hopper**  
**Executive Chairman**  
Imugene Limited

Telephone: +61 2 9007 5585  
Facsimile: +61 3 9822 7735  
Website: <http://www.imugene.com>

**Justyn Stedwell/Phillip Hains**  
**Joint Company Secretaries**  
Imugene Limited

Telephone: +61 3 9824 5254  
Facsimile: +61 3 9822 7735  
Website: <http://www.imugene.com>